-DOCSTART- -X- O
Acute -X- _ B-Patient
diarrhoea -X- _ I-Patient
is -X- _ O
a -X- _ O
leading -X- _ O
cause -X- _ O
of -X- _ O
child -X- _ O
mortality -X- _ O
in -X- _ O
developing -X- _ O
countries. -X- _ O
Principal -X- _ O
pathogens -X- _ O
include -X- _ O
Escherichia -X- _ O
coli -X- _ O
, -X- _ O
rotaviruses -X- _ O
, -X- _ O
and -X- _ O
noroviruses. -X- _ O
90 -X- _ O
% -X- _ O
of -X- _ O
diarrhoeal -X- _ O
deaths -X- _ O
are -X- _ O
attributable -X- _ O
to -X- _ O
inadequate -X- _ O
sanitation. -X- _ O
Acute -X- _ O
diarrhoea -X- _ O
is -X- _ O
the -X- _ O
second -X- _ O
leading -X- _ O
cause -X- _ O
of -X- _ O
overall -X- _ O
childhood -X- _ O
mortality -X- _ O
and -X- _ O
accounts -X- _ O
for -X- _ O
18 -X- _ O
% -X- _ O
of -X- _ O
deaths -X- _ O
among -X- _ O
children -X- _ O
under -X- _ O
five. -X- _ O
In -X- _ O
2004 -X- _ O
an -X- _ O
estimated -X- _ O
1.5 -X- _ O
million -X- _ O
children -X- _ O
died -X- _ O
from -X- _ O
diarrhoea -X- _ O
, -X- _ O
with -X- _ O
80 -X- _ O
% -X- _ O
of -X- _ O
deaths -X- _ O
occurring -X- _ O
before -X- _ O
the -X- _ O
age -X- _ O
of -X- _ O
two. -X- _ O
Treatment -X- _ O
goals -X- _ O
are -X- _ O
to -X- _ O
prevent -X- _ O
dehydration -X- _ O
and -X- _ O
nutritional -X- _ O
damage -X- _ O
and -X- _ O
to -X- _ O
reduce -X- _ O
duration -X- _ O
and -X- _ O
severity -X- _ O
of -X- _ O
diarrhoeal -X- _ O
episodes. -X- _ O
The -X- _ O
recommended -X- _ O
therapeutic -X- _ O
regimen -X- _ O
is -X- _ O
to -X- _ O
provide -X- _ O
oral -X- _ O
rehydration -X- _ O
solutions -X- _ O
( -X- _ O
ORS -X- _ O
) -X- _ O
and -X- _ O
to -X- _ O
continue -X- _ O
feeding. -X- _ O
Although -X- _ O
ORS -X- _ O
effectively -X- _ O
mitigates -X- _ O
dehydration -X- _ O
, -X- _ O
it -X- _ O
has -X- _ O
no -X- _ O
effect -X- _ O
on -X- _ O
the -X- _ O
duration -X- _ O
, -X- _ O
severity -X- _ O
, -X- _ O
or -X- _ O
frequency -X- _ O
of -X- _ O
diarrhoeal -X- _ O
episodes. -X- _ O
Adjuvant -X- _ O
therapy -X- _ O
with -X- _ O
micronutrients -X- _ B-Intervention
, -X- _ I-Intervention
probiotics -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
antidiarrhoeal -X- _ I-Intervention
agents -X- _ I-Intervention
may -X- _ O
thus -X- _ O
be -X- _ O
useful. -X- _ O
The -X- _ O
WHO -X- _ O
recommends -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
zinc -X- _ B-Intervention
tablets -X- _ I-Intervention
in -X- _ I-Intervention
association -X- _ I-Intervention
with -X- _ I-Intervention
ORS. -X- _ I-Intervention
The -X- _ O
ESPGHAN -X- _ O
/ -X- _ O
ESPID -X- _ O
treatment -X- _ O
guidelines -X- _ O
consider -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
racecadotril -X- _ B-Intervention
, -X- _ I-Intervention
diosmectite -X- _ I-Intervention
, -X- _ I-Intervention
or -X- _ I-Intervention
probiotics -X- _ I-Intervention
as -X- _ I-Intervention
possible -X- _ I-Intervention
adjunctive -X- _ I-Intervention
therapy -X- _ I-Intervention
to -X- _ I-Intervention
ORS. -X- _ I-Intervention
Only -X- _ B-Outcome
racecadotril -X- _ I-Outcome
and -X- _ I-Outcome
diosmectite -X- _ I-Outcome
reduce -X- _ I-Outcome
stool -X- _ I-Outcome
output -X- _ I-Outcome
, -X- _ O
but -X- _ O
no -X- _ B-Outcome
treatment -X- _ I-Outcome
has -X- _ I-Outcome
yet -X- _ I-Outcome
been -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ O
reduce -X- _ O
hospitalisation -X- _ O
rate -X- _ O
or -X- _ O
mortality. -X- _ O
Appropriate -X- _ O
management -X- _ O
with -X- _ O
validated -X- _ O
treatments -X- _ O
may -X- _ O
help -X- _ O
reduce -X- _ O
the -X- _ O
health -X- _ O
and -X- _ O
economic -X- _ O
burden -X- _ O
of -X- _ O
acute -X- _ B-Patient
diarrhoea -X- _ I-Patient
in -X- _ I-Patient
children -X- _ I-Patient
worldwide -X- _ O
. -X- _ O

